Payment overview · 2025
General Payments
$914.72
86 reported records · 7 companies
Healthcare provider profile · identity verified
Derek Murphy, MD
Allopathic & Osteopathic Physicians|Internal Medicine · NOBLESVILLE, IN · NPI 1619014628
Verified facts
What the public records show
CMS Open Payments records show Derek Murphy, MD received $914.72 in general payments during 2025 across 86 reported records.
Vanda Pharmaceuticals Inc. accounted for 43.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 13 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Nexletol, Vraylar, Xyosted.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARMOUR THYROID as an associated drug or biological on 50 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Armour Thyroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Vraylar by this doctor in 2024.
Antares Pharma, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XYOSTED as an associated drug or biological on 18015 records involving 7619 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Xyosted by this doctor in 2024.
Esperion Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXLETOL as an associated drug or biological on 24230 records involving 12642 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Nexletol by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $393.61 | 43.0% | 26 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $241.90 | 26.4% | 32 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $191.13 | 20.9% | 22 | 2025 |
| Antares Pharma, Inc. | Unresolved — no canonical attribution shown | $51.57 | 5.6% | 3 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $15.86 | 1.7% | 1 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $13.65 | 1.5% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $7.00 | 0.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $914.72 | 86 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $393.61 | 26 | 2025 |
Source payment records
|
|||||
| HETLIOZ Normalized: hetlioz |
Drug | Vanda Pharmaceuticals Inc. | $393.61 | 26 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $191.13 | 22 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $154.10 | 15 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $76.41 | 12 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $69.94 | 11 | 2025 |
Source payment records
|
|||||
| XYOSTED Normalized: xyosted |
Drug | Antares Pharma, Inc. | $51.57 | 3 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $15.86 | 1 | 2025 |
Source payment records
|
|||||
| AJOVY Normalized: ajovy |
Biological | Teva Pharmaceuticals USA, Inc. | $13.65 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $7.00 | 1 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $6.50 | 4 | 2025 |
Source payment records
|
|||||
| VIBERZI Normalized: viberzi |
Drug | ABBVIE INC. | $6.50 | 4 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $2.93 | 2 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| NEXLETOL nexletol |
2025 | Nexletol | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 32 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| XYOSTED xyosted |
2025 | Xyosted | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | ARMOUR THYROID open payments reported associated product |
CMS Open Payments — General Payments 50 supporting records · 11 recipient NPIs · example record 1201517088 |
Armour Thyroid · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| Antares Pharma, Inc. Exact reporting entity; no affiliate inference |
2025 | XYOSTED open payments reported associated product |
CMS Open Payments — General Payments 18015 supporting records · 7619 recipient NPIs · example record 1235880452 |
Xyosted · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Esperion Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | NEXLETOL open payments reported associated product |
CMS Open Payments — General Payments 24230 supporting records · 12642 recipient NPIs · example record 1243949989 |
Nexletol · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 168 | 44 |
| Levothyroxine Sodium | Levothyroxine Sodium | 165 | 44 |
| Mounjaro | Tirzepatide | 148 | 18 |
| Atorvastatin Calcium | Atorvastatin Calcium | 145 | 45 |
| Amlodipine Besylate | Amlodipine Besylate | 114 | 32 |
| Liothyronine Sodium | Liothyronine Sodium | 106 | 31 |
| Progesterone | Progesterone, Micronized | 88 | 23 |
| Ozempic | Semaglutide | 81 | suppressed |
| Ezetimibe | Ezetimibe | 79 | 20 |
| Montelukast Sodium | Montelukast Sodium | 78 | 25 |
| Lisinopril | Lisinopril | 73 | 24 |
| Duloxetine Hcl | Duloxetine Hcl | 67 | 13 |
| Alprazolam | Alprazolam | 63 | 11 |
| Gabapentin | Gabapentin | 61 | 19 |
| Celecoxib | Celecoxib | 60 | 11 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 59 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 58 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 55 | 15 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 49 | 29 |
| Metoprolol Succinate | Metoprolol Succinate | 49 | 12 |
| Testosterone Cypionate | Testosterone Cypionate | 47 | suppressed |
| Clonazepam | Clonazepam | 46 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 45 | 18 |
| Prednisone | Prednisone | 45 | 34 |
| Furosemide | Furosemide | 44 | suppressed |
| Chlorthalidone | Chlorthalidone | 43 | 13 |
| Escitalopram Oxalate | Escitalopram Oxalate | 42 | 16 |
| Pregabalin | Pregabalin | 42 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 41 | 11 |
| Jardiance | Empagliflozin | 41 | suppressed |
| Metformin Hcl | Metformin Hcl | 41 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 41 | 12 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 39 | suppressed |
| Losartan Potassium | Losartan Potassium | 38 | 11 |
| Nebivolol Hcl | Nebivolol Hcl | 38 | 11 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 38 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 38 | suppressed |
| Januvia | Sitagliptin Phosphate | 36 | suppressed |
| Omeprazole | Omeprazole | 36 | suppressed |
| Unithroid | Levothyroxine Sodium | 36 | 11 |
| Sertraline Hcl | Sertraline Hcl | 35 | 11 |
| Synthroid | Levothyroxine Sodium | 34 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 34 | 12 |
| Armour Thyroid | Thyroid,pork | 33 | suppressed |
| Carvedilol | Carvedilol | 32 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 32 | suppressed |
| Spironolactone | Spironolactone | 32 | 12 |
| Vraylar | Cariprazine Hcl | 32 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 31 | suppressed |
| Azithromycin | Azithromycin | 31 | 26 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 31 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 29 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 29 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 25 | suppressed |
| Estradiol | Estradiol | 25 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 25 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 24 | suppressed |
| Diazepam | Diazepam | 24 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 24 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 24 | suppressed |
| Dextroamphetamine Sulfate | Dextroamphetamine Sulfate | 23 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 23 | suppressed |
| Dayvigo | Lemborexant | 22 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 22 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 22 | suppressed |
| Temazepam | Temazepam | 22 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 22 | suppressed |
| Allopurinol | Allopurinol | 21 | suppressed |
| Atenolol | Atenolol | 21 | suppressed |
| Seglentis | Tramadol Hcl/Celecoxib | 21 | suppressed |
| Edarbi | Azilsartan Medoxomil | 20 | suppressed |
| Valsartan | Valsartan | 20 | suppressed |
| Fluconazole | Fluconazole | 19 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 19 | suppressed |
| Vascepa | Icosapent Ethyl | 19 | suppressed |
| Bupropion Xl | Bupropion Hcl | 18 | suppressed |
| Memantine Hcl | Memantine Hcl | 18 | suppressed |
| Olanzapine | Olanzapine | 18 | suppressed |
| Zaleplon | Zaleplon | 18 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 17 | suppressed |
| Myrbetriq | Mirabegron | 17 | suppressed |
| Potassium Chloride | Potassium Chloride | 17 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 17 | suppressed |
| Amoxicillin | Amoxicillin | 16 | 12 |
| Anastrozole | Anastrozole | 16 | suppressed |
| Fenofibrate | Fenofibrate | 16 | suppressed |
| Glimepiride | Glimepiride | 16 | suppressed |
| Finasteride | Finasteride | 15 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 15 | suppressed |
| Repatha Sureclick | Evolocumab | 15 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 14 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 13 | suppressed |
| Febuxostat | Febuxostat | 13 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 13 | suppressed |
| Mupirocin | Mupirocin | 13 | suppressed |
| Nexletol | Bempedoic Acid | 13 | suppressed |
| Simvastatin | Simvastatin | 13 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 13 | suppressed |
| Alprazolam Er | Alprazolam | 12 | suppressed |
| Carisoprodol | Carisoprodol | 12 | suppressed |
| Ibuprofen | Ibuprofen | 12 | suppressed |
| Irbesartan | Irbesartan | 12 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 12 | suppressed |
| Movantik | Naloxegol Oxalate | 12 | suppressed |
| Xyosted | Testosterone Enanthate | 12 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 12 | suppressed |
| Belsomra | Suvorexant | 11 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 11 | 11 |
| Fluocinonide | Fluocinonide | 11 | suppressed |
| Metaxalone | Metaxalone | 11 | suppressed |
| Otezla | Apremilast | 11 | suppressed |
| Primidone | Primidone | 11 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 11 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $914.72 · 86 records | Vanda Pharmaceuticals Inc. | AJOVY, CREON, FANAPT, HETLIOZ, LINZESS, NEXLETOL, QULIPTA, UBRELVY, VIBERZI, VOQUEZNA, VRAYLAR, XIFAXAN, XYOSTED | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Nexletol play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error